Goldman Sachs Adjusts Price Target on APA to $47 From $44
Goldman Sachs has updated its price target for APA Corporation, increasing it from $44 to $47.
Economy · News reference
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
APAARWRASNDCAICAVACMGCOINCRCLCRUSDGXDIADVNEOGFANGFPSILMNITBIWMJETSOIHQCOMQQQQRVORVTYSWKSTANTEMTMOTXRHVOOWINGXLEXLUXLYXOPXRT
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Raymond James Adjusts Price Target on APA Corporation to $58
Raymond James has updated its price target for APA Corporation, raising it from $54 to $58.
Susquehanna Maintains Positive on APA, Raises Price Target to $58
Susquehanna analyst Biju Perincheril maintains APA (NASDAQ:APA) with a Positive and raises the price target from $47 to $58.
Arrowhead Pharmaceuticals Receives UK Marketing Authorisation for REDEMPLO
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for REDEMPLO (plozasiran) to treat adults with Familial Chylomicronaemia Syndrome (FCS).
Arrowhead Pharmaceuticals Announces REDEMPLO (plozasiran) Availability in England and Wales
Arrowhead Pharmaceuticals announced that REDEMPLO (plozasiran) is now available on the NHS for adults in England and Wales with Familial Chylomicronaemia Syndrome (FCS).
Top 3 Health Care Stocks That Could Blast Off In October
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.